Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AD Detect-Prevent

Financiado

Alzheimer s Disease AD Detect Prevent Presymptomatic AD detection and prev...

Alzheimer s Disease AD Detect Prevent Presymptomatic AD detection and prevention Alzheimer’s disease (AD) is central to the rapidly growing and crushing ageing challenge that threatens to economically undermine today’s health care system. AD prevalence will grow to over 100m cases in 2050. AD is incurable, but... ver más

30/04/2022

Brain+ ApS

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

BRAIN APS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 7 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-04-30

EIC-FTI-2018-2020: Fast Track to Innovation (FTI)

I+D

Cerrada hace 6 años

0% 76% 100%

7 Participantes

Brain+ ApS

2.20M€ | Lider

SUISSE APPLICATION SECURITY...

215.65K€ | Participante

AUH

160.31K€ | Participante

UOXF

184.92K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 42 meses Fecha Inicio: 2018-10-04
Fecha Fin: 2022-04-30

Líder del proyecto

BRAIN APS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Descripción del proyecto Alzheimer’s disease (AD) is central to the rapidly growing and crushing ageing challenge that threatens to economically undermine today’s health care system. AD prevalence will grow to over 100m cases in 2050. AD is incurable, but can be prevented. Detecting pre-symptomatic signs of AD in at-risk groups and intervening early may be the only viable solution. Our target is to bring to market a novel ICT tool, named ‘AD Shield’, that screens for and detects pre-symptomatic stage cognitive decline related to AD, and creates a personalized program for each individual user to strengthen weakened cognitive abilities, thus building cognitive reserve and reducing AD risk. Brain+ will collaborate with world leading neuroscientists to validate this ICT tool. Completion of the tasks described in the workplan will secure the remaining development adaptation combination and validation of the existing technological breakthroughs of the Brain+ method and ICT platform, including the Oxford University’s new highly sensitive cognitive assessment method. The end product will be a scientifically validated, effective, economic, engaging and easily accessible method for pre-symptomatic detection of AD and preventative training. 'AD Shield' can be value created and costs saved of up to €60.000 per patient for the healthcare payers, and at EU level saving can amount to €7bn-108bn direct costs per year and €155bn informal care costs per year. Success stemmed from this phase 2 project will also empower AD at-risk groups and allow them to stay active in the labour market for longer. The combination of costs saved will ultimately boost EU competitiveness.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores